Log in

NASDAQ:INNT - Innovate Biopharmaceuticals Stock Price, Forecast & News

$0.66
0.00 (0.00 %)
(As of 01/17/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.65
Now: $0.66▼
$0.67
50-Day Range
$0.48
MA: $0.65▼
$0.78
52-Week Range
$0.40
Now: $0.66▼
$4.32
Volume208,868 shs
Average Volume438,317 shs
Market Capitalization$23.68 million
P/E RatioN/A
Dividend YieldN/A
Beta-2.58
Innovate Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INNT
Previous Symbol
CUSIPN/A
CIK1551986
Webhttp://www.innovatebiopharma.com/
Phone919-275-1933

Debt

Debt-to-Equity RatioN/A
Current Ratio0.74
Quick Ratio0.74

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.14) per share
Price / Book-4.71

Profitability

EPS (Most Recent Fiscal Year)($0.98)
Net Income$-24,160,000.00
Net MarginsN/A
Return on Equity-1,557.56%
Return on Assets-174.02%

Miscellaneous

Employees8
Outstanding Shares35,884,000
Market Cap$23.68 million
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive INNT News and Ratings via Email

Sign-up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:INNT Rates by TradingView

5G Flaw Exposed: $5 Stock Holds Key To $12 Trillion Opportunity (Ad)


A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

Innovate Biopharmaceuticals (NASDAQ:INNT) Frequently Asked Questions

What is Innovate Biopharmaceuticals' stock symbol?

Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT."

How were Innovate Biopharmaceuticals' earnings last quarter?

Innovate Biopharmaceuticals Inc (NASDAQ:INNT) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.05. View Innovate Biopharmaceuticals' Earnings History.

When is Innovate Biopharmaceuticals' next earnings date?

Innovate Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Innovate Biopharmaceuticals.

What price target have analysts set for INNT?

1 Wall Street analysts have issued 1-year target prices for Innovate Biopharmaceuticals' shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Innovate Biopharmaceuticals' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 1,415.2% from the stock's current price. View Analyst Price Targets for Innovate Biopharmaceuticals.

What is the consensus analysts' recommendation for Innovate Biopharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovate Biopharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innovate Biopharmaceuticals.

Has Innovate Biopharmaceuticals been receiving favorable news coverage?

News headlines about INNT stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Innovate Biopharmaceuticals earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Innovate Biopharmaceuticals.

Are investors shorting Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,830,000 shares, an increase of 8.9% from the December 15th total of 1,680,000 shares. Based on an average trading volume of 431,300 shares, the short-interest ratio is presently 4.2 days. Approximately 8.0% of the company's shares are short sold. View Innovate Biopharmaceuticals' Current Options Chain.

Who are some of Innovate Biopharmaceuticals' key competitors?

What other stocks do shareholders of Innovate Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO), Corbus Pharmaceuticals (CRBP), Axsome Therapeutics (AXSM), Iterum Therapeutics (ITRM), Momo (MOMO), Alibaba Group (BABA), AcelRx Pharmaceuticals (ACRX), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Inovio Pharmaceuticals (INO).

Who are Innovate Biopharmaceuticals' key executives?

Innovate Biopharmaceuticals' management team includes the folowing people:
  • Mr. Sandeep Laumas M.D., CEO & Exec. Chairman (Age 50)
  • Mr. Jay P. Madan M.S., Founder, Pres, Chief Bus. Officer, Interim Principal Fin & Accounting Officer and Director (Age 53)
  • Dr. Christopher P. Prior, Consultant (Age 66)
  • Jerry Gardner M.D., Head of Clinical Strategy
  • Dr. Patrick H. Griffin, Chief Medical Officer (Age 64)

How do I buy shares of Innovate Biopharmaceuticals?

Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Innovate Biopharmaceuticals' stock price today?

One share of INNT stock can currently be purchased for approximately $0.66.

How big of a company is Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals has a market capitalization of $23.68 million. The company earns $-24,160,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Innovate Biopharmaceuticals employs 8 workers across the globe.View Additional Information About Innovate Biopharmaceuticals.

What is Innovate Biopharmaceuticals' official website?

The official website for Innovate Biopharmaceuticals is http://www.innovatebiopharma.com/.

How can I contact Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]


MarketBeat Community Rating for Innovate Biopharmaceuticals (NASDAQ INNT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  191 (Vote Outperform)
Underperform Votes:  203 (Vote Underperform)
Total Votes:  394
MarketBeat's community ratings are surveys of what our community members think about Innovate Biopharmaceuticals and other stocks. Vote "Outperform" if you believe INNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2020 by MarketBeat.com Staff

Featured Article: Diversification
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel